Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Meanwhile I will be flipping mine all the way to $50.:)
Nice volume.Sometimes I think of the old play 'Waiting for Godot' when contemplating RGBP.LOL !!
These shares are held in a trust controlled by Dr Koos.Alot of uses for these shares- an insurance policy to prevent a hostile takeover is one bonus.In the event of a sale the increase in share price would benefit BMSN shareholders.Or shares could be sold to finance day to day operations of BMSN and or RGBP.These are shares already printed and would not cause dilution.
The high volume is stunning and makes me think we may see 20's by the end of the week.Certainly RGBP has been way under valued and IMO the pps should be a dollar.Go RGBP !!
Very good news !!
This information was previously released.It has since become very significant after the failure of Incyte's JAK1 inhibitor.Perhaps RGBP's approach may be more successful in killing big tumors.If it is it would be huge news.
http://www.fiercebiotech.com/story/jak-inhibition-solid-tumors-flops-forcing-incyte-pull-plug-slate-trials/2016-02-11
Jakafi has failed to help patients in a late-stage study for pancreatic cancer, and Incyte feels that it now has all the data it needs to prove that a JAK1 inhibitor is the wrong way to go in solid tumors.
Just ahead of its annual numbers release, Incyte reported today that it is slamming the brakes on a range of studies for Jakafi as well as the experimental INCB39110, another JAK1. Already halted on one colon cancer trial failure, Incyte is ending the Phase III pancreatic cancer study, a separate midstage trial in colorectal cancer, a Phase II for breast and lung cancers and a dose-ranging trial for INCB39110 in pancreatic cancer.
The only way I have found is to get a trading platform and use its free 30 day test drive.Google MM Level II Activity Log.I wanted to post a link but it may have been a violation of terms of service.
Level II MM Activity Log
Very thoughtful response by Dr Lander.Thanks for sharing GM !!
Actually I think it is more likely because of the NIH capability using their bots that can run experiments 24/7 as has been previously posted here.
Results from the NIH collaboration already ?
IMO people are buying up cheap shares.This stock is a flippers dream as we have seen for two years now.
Not sure if a conclusion can be drawn.We have seen a week of a similar range for RGBP even with good news,no bump upward.I have been trying to figure out why no breakout ?My conclusion is that the price is kept low by RGBP and or BMSN selling shares.
Post 23745 is stickied 1Eye
no issues here
If you dont care for the game you could sell your position and move on to another stock.You either believe in the company or you dont.If you like what you see ride the roller coaster to profit or sell and move on.Pretty simple really.
nice gain today I hope to see an EOD close in the green.
Your post is a personal attack and I have to delete your post.Not every post deserves a response.Just say'n.
Very informative letter from Dr Lander.The approach to moving ahead is focused rather than a shotgun approach.
The huge volume today was as good an indication as you can get,that we are on the right path.We probably will see news this week that will spark a run.
The pattern of no climb after good news has been a problem for a year or more.Its almost as if the company doesnt want to see upward movement because the teasury cant afford to pay out big money at the moment.If the longs sold all their shares at $4 thats pretty substantial.I am content to wait for the end of trials or a buyout offer,both events will see upward movement,but a buyout will send the pps to the moon as they say.Those that were hoping for quick money have been disappointed yet again lol !
Very very nice.Thanks Jack !!
FDA approval should have been the catalyst.NIH partnership should have been enough to push this upward,but it hasnt.The start of the clinical trial should,but this has been the pattern for over a year.Good news doesnt translate into upward movement.The trial will be proof of concept.If it is shown that RGBP can cure cancer then finally we will be golden.At this point its just theory.
Some people just cant get past what they view as the villain of this saga.The flip side is that Dr Koos has put together a superb team of scientists that have one product approved for human trials and another to follow.Dr Koos has not hyped or mislead the investors and has kept us in the loop with informative pr's.No false promises just results.Who benefits from low share prices short term ? Anyone who want to flip for pennies as well as those who are long.I buy when the price is low and I hold my shares for as long as it takes.This company is IMO a diamond in the rough.Its all about the science which offers hope for people who would possibly die from cancer.History is being made here and I feel great about my very small part in this quest.
Both ichim's have everything to gain from RGBP being successful by virtue of their equity position.I would also remind people that Dr T Ichim remains with RGBP as Senior Research Consultant.
http://www.regenbiopharmainc.com/management-team.html
Also found on the company web site is this tid bit that I had forgotten about.
http://www.regenbiopharmainc.com/product-pipeline.html
IF RGEN were to be bought out,BATU would be a good fall back position for the Ichims since they could reinvest their new wealth.
I hope Monday starts RGBP's climb to dollar land.Exciting stuff.IMO the company is very undervalued it should trade in the $1-4 range.Successful trials and FDA approval for Dcel will push us even higher.
Thats one possibility,but that in itself would not delay the financials.There may be something else that would cause the company extra cost.They may be negotiating something and it wont be final for another week or so.
I guess we will wait for the report, which the 10k stated will be filed by 15 Jan ? I wonder why the delay ?One can only speculate I guess.
Agreed on your analysis Schuller.Looking forward to the New Year!!
We arent going to see much movement upward until after the holidays,its really one of the slow periods for any stock.People are relaxing and arent investing new money.Nor do I exect to se much until after the results are in for the first stage of clinicals.It would be nice to see dcel get FDA approval,but if Koos has learned something he will have CRL do a safety study,then get FDA approval.
What should world class scientists be paid ? We are lucky to have them.
Yep I added more this morning because I think this will explode at some point.Paid .18 per share and it filled right away,that was when it was around .17.
Thanks Peter.I think I will stickie it.
Reminder the market closes in 15 minutes.Have an awesome Christmas and we will see you Monday.Be safe !!
Cautious start beofre we go up or the flipping starts lol
I re-read the 8k to better understand what the two parties will gain from this collaberation.If I understand this RGBP handles commercial applications of any inventions ?
The market closes on the 24th at 1,so I think this week and probably next week will be pretty slow.Have a Merry Xmas everyone !!